Alexander M, Cheng Y, Lee SH, Passaro A, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib,
in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and
resource utilization results from the PALOMA-3 study. Eur J Cancer 2025;227:115624.
PMID: 40730077
![]() |
![]() |
![]() |